Table 3. . Modern chemotherapy agents in melanoma.
| Study (author) | Treatment arms | Number per arm | ORR (CR/PR) | CRR (CR/PR/SD) | Median PFS/TTP | Median OS | Ref. |
|---|---|---|---|---|---|---|---|
| Phase II, tasisulam (Kirkwood et al.) | Tasisulam | 68 | 18% | 47.1% | 2.6 months | 9.6 months | [45] |
| Phase II, paclitaxel plus elesclomol or placebo (O'Day et al.) | Paclitaxel plus placebo | 28 | 3% | – | – | 7.8 months | [29] |
| Paclitaxel plus elesclomol | 53 | 15% | – | – | 11.9 months | ||
| Phase III (SYMMETRY), paclitaxel plus placebo or elesclomol (O'Day et al.) | Paclitaxel plus placebo | 326 | 4% | 22% | 1.9 months | 11.4 months | [25] |
| Paclitaxel plus elesclomol | 325 | 7% | 18% | 3.4 months | 10.6 months | ||
| Phase II, nab-paclitaxel (Hersh et al.) | Nab-paclitaxel (chemotherapy naive) | 37 | 21.6% | 48.6% | 4.5 months | 9.6 months | [46] |
| Nab-paclitaxel (pretreated) | 37 | 2.7% | 37.8% | 3.5 months | 12.1 months | ||
| Phase II, carboplatin plus nab-paclitaxel (Kottschade et al.) | Carboplatin plus nab-paclitaxel (chemotherapy naive) | 41 | 25.6% | – | 4.5 months | 11.1 months | [47] |
| Carboplatin plus nab-paclitaxel (pretreated) | 35 | 8.8% | – | 4.1 months | 10.9 months | ||
| Phase III, DTIC versus nab-paclitaxel (Hersh et al.; Del Vecchio et al.) | DTIC | 265 | 11% | 27% | 2.5 months | 10.5 months | [48,49] |
| Nab-paclitaxel | 264 | 15% | 39% | 4.8 months | 12.6 months | ||
CRR: Clinical response rate; DTIC: Dimethyl triazeno imidazole carboxamide; ORR: Overall response rate; OS: Overall survival; PFS: Progression-free survival; PR: Partial response; SD: Stable disease; TTP: Time to progression.